SUNPHARMASun Pharmaceutical
Pharma · Pharmaceuticals · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Sun Pharmaceutical operates in the Pharmaceuticals space within the Pharma sector.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
None of the 16 pattern scanners currently detects a setup on SUNPHARMA — signals appear here automatically when one forms (checked on every data refresh). The Trade Plan on the right always provides stop-loss and target levels regardless.
The picture
- • Profit growth: 27.4% YoY
- • Debt/Equity: 0.06
- • Promoter holding: 55.6%
- • MACD: fresh bullish crossover
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 39
Bull case
- • Profit growth: 27.4% YoY
- • Debt/Equity: 0.06
- • Promoter holding: 55.6%
- • MACD: fresh bullish crossover
Bear case
- • RSI: 36
- • Price vs EMA21: below
- • 1-month return: -5.9%
- • 1-month vs NIFTY: -3.0% relative
Key risks
- • Momentum is fading versus the broader market
- • RSI: 36
- • Price vs EMA21: below
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹32.20). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.